超级军网喜讯：中国研发的治疗H7N9危重病人注射液获准生产
来源：百度文库 编辑：超级军网 时间：2024/04/28 11:31:06
http://news.rzw.com.cn/guonei/guoneiyaowen/2013/0406/28044.shtml
【我国研发的用于治疗流感危重病人的注射液获准生产】帕拉米韦获准生产将为H7N9人禽流感患者提供新的治疗手段。这个药是由军事医科学院自主研发，能有效对抗流感病毒。据了解，目前我国已建立了流感药物应急生产和储备体系，包括预防和治疗药物，为国家自主防控流感疫情提供了药品保障。(央视记者余静英)
【我国研发的用于治疗流感危重病人的注射液获准生产】帕拉米韦获准生产将为H7N9人禽流感患者提供新的治疗手段。这个药是由军事医科学院自主研发，能有效对抗流感病毒。据了解，目前我国已建立了流感药物应急生产和储备体系，包括预防和治疗药物，为国家自主防控流感疫情提供了药品保障。(央视记者余静英)
【我国研发的用于治疗流感危重病人的注射液获准生产】帕拉米韦获准生产将为H7N9人禽流感患者提供新的治疗手段。这个药是由军事医科学院自主研发，能有效对抗流感病毒。据了解，目前我国已建立了流感药物应急生产和储备体系，包括预防和治疗药物，为国家自主防控流感疫情提供了药品保障。(央视记者余静英)
【我国研发的用于治疗流感危重病人的注射液获准生产】帕拉米韦获准生产将为H7N9人禽流感患者提供新的治疗手段。这个药是由军事医科学院自主研发，能有效对抗流感病毒。据了解，目前我国已建立了流感药物应急生产和储备体系，包括预防和治疗药物，为国家自主防控流感疫情提供了药品保障。(央视记者余静英)
这是好东西
Peramivir is an experimental antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. It has been authorized for the emergency use of treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza.[1]
Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells.
The development of peramivir is supported by the US Department of Health and Human Services as part of the US government's effort to prepare against the threat of an influenza pandemic.[2]
Peramivir is already available in Japan as RAPIACTA (R) and also available in South Korea as PERAMIFLU. Peramivir is currently the only intravenous option for treating swine flu. The drug is in Phase III studies in US.[3][4]
In October 2009, it was reported that the experimental antiviral drug peramivir had been effective in treating serious cases of swine flu.[5] On October 23, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for Peramivir, allowing the use of the drug in intravenous form for hospitalized patients only in cases where the other available methods of treatment are ineffective or unavailable;[6] for instance, if oseltamivir (Tamiflu) resistance develops and a person is unable to take Relenza via the inhaled route. The Emergency Use Authorization expired on June 23, 2010.
Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells.
The development of peramivir is supported by the US Department of Health and Human Services as part of the US government's effort to prepare against the threat of an influenza pandemic.[2]
Peramivir is already available in Japan as RAPIACTA (R) and also available in South Korea as PERAMIFLU. Peramivir is currently the only intravenous option for treating swine flu. The drug is in Phase III studies in US.[3][4]
In October 2009, it was reported that the experimental antiviral drug peramivir had been effective in treating serious cases of swine flu.[5] On October 23, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for Peramivir, allowing the use of the drug in intravenous form for hospitalized patients only in cases where the other available methods of treatment are ineffective or unavailable;[6] for instance, if oseltamivir (Tamiflu) resistance develops and a person is unable to take Relenza via the inhaled route. The Emergency Use Authorization expired on June 23, 2010.
莫非是板蓝根注射液？
鱼肠草注射液使我国成为地球上唯一一个允许超过3种单质存在于注射液中的国家（51种），这个能不能刷新纪录呢
鱼肠草注射液使我国成为地球上唯一一个允许超过3种单质存在于注射液中的国家（51种），这个能不能刷新纪录呢
有人科普了，这药是自主研发？。。。。。。。千言万语只有一个词：呵呵